JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Setting

Ordered before 17:30, shipped today - Support: (012) 800 456 789

Track Your Order

Home
Search results for: 'c-Abl'

Search results for: 'c-Abl'

A3020 (R)-Crizotinib

2 Citation

Target: c-MET

Summary: C-MET/ALK inhibitor,potent and ATP-competitve

insoluble in H2O; insoluble in EtOH; ≥7.51 mg/mL
B5846 Radotinib(IY-5511)

Target: PDGFR|Bcr-Abl

Summary: Bcr-Abl tyrosine kinase inhibitor

≥13.73 mg/mL
A8325 Tivantinib (ARQ 197)

2 Citation

Target: MET

Summary: C-Met inhibitor,non-ATP-competitive

≥18.47 mg/mL
A8476 MK-2461

Target: FLT3|PDGFR|MET|Ron

Summary: C-Met (WT/mutants) inhibitor

≥24.8 mg/mL
B4664 T-5224

10 Citation

Target: AP-1|MMP

Summary: C-Fos/AP-1 inhibitor

≥25.88 mg/mL
A5703 BMS-777607

Target: MET

Summary: C-Met inhibitor, potent and selective

≥25.65 mg/mL
A8329 R428

10 Citation

Summary: Selective Axl inhibitor

≥25 mg/mL
A8370 Axitinib (AG 013736)

1 Citation

Target: VEGFR|PDGFR|c-Kit

Summary: VEGFR1/ c-Kit inhibitor

insoluble in H2O; ≥19.3 mg/mL
A8448 INCB28060

Target: c-MET

Summary: C-Met inhibitor,ATP-competitive and novel

insoluble in EtOH; insoluble in H2O; ≥5.15 mg/mL
B5832 Altiratinib

1 Citation

Target: FLT3|VEGFR|Trk Receptors|c-MET|Tie-2

Summary: c-MET/TIE-2/VEGFR inhibitor

≥21.55 mg/mL